Literature DB >> 20601540

Maternal and fetal thrombophilia in intrauterine growth restriction in the presence or absence of maternal hypertensive disease.

Paola Pileri1, Franca Franchi, Irene Cetin, Chiara Mandò, Patrizio Antonazzo, Buthaina Ibrahim, Federica Rossi, Eugenia Biguzzi.   

Abstract

Intrauterine growth restriction (IUGR) depends on the placental capacity to transfer oxygen and nutrients from the maternal to the fetal circulation. Placental insufficiency may be caused by impairment of the maternal or fetal circulation by a thrombotic event, possibly associated with thrombophilic disorders. The goals of our study were to define the role of maternal/fetal gain-of-function factor V Leiden and prothrombin G20210A mutations in the development of IUGR and to evaluate whether maternal pregnancy-induced hypertensive diseases would modify any such association. This is a case-control study: controls were 259 normal pregnancies, cases were 77 IUGR, 28 with and 49 without preeclampsia (PE) or pregnancy-induced hypertension (PIH). An association was found between IUGR and fetal thrombophilia (OR 2.09 CI 95% 1-4.5). The association was stronger in IUGR without PE and PIH (OR 2.9 CI 95% 1.3-6.6). This suggests a role for the fetal genotype in the development of IUGR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20601540     DOI: 10.1177/1933719110371516

Source DB:  PubMed          Journal:  Reprod Sci        ISSN: 1933-7191            Impact factor:   3.060


  2 in total

1.  Candidate single-nucleotide polymorphisms and cerebral palsy: A case-control study.

Authors:  Xiao-Guang He; Q I Peng; Yan-Hua Chen; Ting He; Hui Huang; Ze-Ke Ma; Xue-Jin Fan; Ling Luo; Shao-Ji Liu; Xiao-Mei Lu
Journal:  Biomed Rep       Date:  2015-09-25

2.  Polymorphisms of Platelet Glycoprotein Receptors and Cell Adhesion Molecules in Fetuses with Fetal Growth Restriction and Their Mothers As Detected with Pyrosequencing.

Authors:  Maria Simou; Evaggelia Kouskouni; Nikolaos Vitoratos; Emmanuel Economou; George Creatsas
Journal:  In Vivo       Date:  2017 Mar-Apr       Impact factor: 2.155

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.